Fulgent Genetics vs Viemed Healthcare
Fulgent Genetics reported revenue of $323 million in fiscal 2025, 1.2 times Viemed Healthcare's $270 million in fiscal 2025. Fulgent Genetics' revenue grew 13.8% in its latest year, and Viemed Healthcare's grew 20.5%. Fulgent Genetics had an operating margin of -28.2%, against 8.5% at Viemed Healthcare. Free cash flow was −$124 million at Fulgent Genetics and $12 million at Viemed Healthcare.
Side by side
| Fulgent Genetics | Viemed Healthcare | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $323M | $270M |
| Revenue growth | 13.8% | 20.5% |
| Revenue growth a year, last 5 years | −5.2% | 15.5% |
| Gross margin | 40.6% | 57.5% |
| Operating margin | −28.2% | 8.5% |
| Net margin | −18.8% | 5.5% |
| Free cash flow | −$124M | $12M |
| Free cash flow margin | −38.5% | 4.4% |
| Return on capital | −8.7% | 12.4% |
| Net debt to EBITDA | — | −0.0x |
| Dividends and buybacks | $11M | $13M |
| Change in diluted share count | 1.8% | 0.1% |
| Last close | $24.78 | $8.61 |
| P/E at the last close | — | 22.7× |
| Insider trades, last 12 months | sold $386,628 | sold $1.6 million |
| Piotroski F-score | 4 of 9 | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Fulgent GeneticsViemed Healthcare
Operating margin
Percent of revenue
Fulgent GeneticsViemed Healthcare
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Fulgent GeneticsViemed Healthcare
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Fulgent Genetics and Viemed Healthcare pages.